



For more information, contact:
Kate Washburn
(616) 308-4047
kate@wondergem.com

FOR IMMEDIATE RELEASE

IMPERIAL ACQUIRES D. ANDERSON & COMPANY FORMING LANDMARK ENTERPRISE

GRAND RAPIDS, Mich. (March 30, 2011)—Imperial announced today that it has completed its purchase of D. Anderson & Company, representing the first corporate acquisition of a patient recruitment organization and increasing Imperial’s global presence within the clinical trial industry.

“This is an important day for Imperial, D. Anderson & Company and the clients we serve around the world,” said Matthew Bissell, president and CEO of Imperial—a privately owned clinical research support organization with offices in Michigan, Pennsylvania and the United Kingdom. “Independently, each company is a global leader respected for quality, integrity and ingenuity. Together, we are a global force, with the capacity to serve clinical trial sponsors regardless of need, size, location or disease sector.”

Steve Swanson, vice president and COO of Imperial, concurred: “United we are optimally positioned to exceed client expectations in the high stakes field of clinical research. The blending of talent and resources will help us meet growing demands for comprehensive services, competitive pricing and global presence.”

Since its founding in 1945, Imperial has become one of the world’s premier support organizations for sponsors, contract research organizations and agencies alike. The company’s unique approach to single-source solutions, the *iWoRx* platform, delivers an integrated suite of services tailored to the specific needs of customers. Clinical research organizations have come to rely on Imperial for expert design, translations, print production, and e-clinical solutions in support of their global trials. Imperial’s logistics staff boasts over 300,000 shipments to more than 82 countries. The company has accelerated time-to-market for hundreds of compounds and has thousands of active protocols under management.

“Today marks the beginning of an exciting new era,” said Diana L. Anderson, Ph.D., president and CEO of D. Anderson & Company. “Clients will benefit from the bandwidth of our intellectual resources, world reach and ability to provide unparalleled support services for international clinical trials.”

With 19 years’ experience spanning five continents and 40 disease indications, Dallas-based D. Anderson & Company develops patient recruitment and retention campaigns for clinical trials. Core competencies include strategic site selection, project management, creative services and clinical staff training. The company’s international business has grown exponentially over the past 3 years and now represents 63 percent of overall sales. Customer geography covers the United States and Europe including 20 countries in Asia and the Pacific Rim. Clients include large and small companies in the pharmaceutical, biotechnology, device and site sectors.

For more information about Imperial, visit www.imperialcrs.com or call (800) 777-2591. For information about D. Anderson & Company, visit www.dandersoncompany.com or call (800) 466-1774.

#